Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro

Cardiovascular Research

Volumn 56, Issue 1, 2002, Pages 64-75

  Busk, Peter K ^a   Bartkova, Jirina ^b   Strøm, Claes C ^a   Wulf Andersen, Linda ^a   Hinrichsen, Rebecca ^a   Christoffersen, Tue E H ^a   Latella, Lucia ^b   Bartek, Jiri ^b   Haunsø, Stig ^a   Sheikh, Søren P ^a  

^a Rigshospitalet   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Gene expression; Hypertrophy; Myocytes; Protein kinases; Signal transduction

Indexed keywords

ANGIOTENSIN; CELL CYCLE PROTEIN; CYCLIN D; CYCLIN DEPENDENT KINASE; DIFFERENTIATION INDUCING FACTOR; DIFFERENTIATION INDUCING FACTOR 1; PHENYLEPHRINE; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; CAENORHABDITIS ELEGANS PROTEINS; CARRIER PROTEINS; CELLS, CULTURED; CYCLIN D1; CYCLIN-DEPENDENT KINASES; CYCLINS; HELMINTH PROTEINS; HYPERTROPHY, LEFT VENTRICULAR; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 0036774313     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(02)00510-2     Document Type: Article

References (51)

1. Chien K.R., Grace A.A., Hunter J.J. Molecular and cellular biology of cardiac hypertrophy and failure. Chien K.R., Molecular basis of cardiovascular disease. 1999;211-250 Saunders, Philadelphia, PA.
2. Agabiti-Rosei E., Muiesan M.L. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J Hypertens Suppl. 16:1998;S53-S58.
3. Chien K.R. Meeting Koch's postulates for calcium signaling in cardiac hypertrophy. J Clin Invest. 105:2000;1339-1342.
4. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
5. Molkentin J.D. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 87:2000;731-738.
6. Sussman M.A., Lim H.W., Gude N., et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.
7. Ding B., Price R.L., Borg T.K., et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res. 84:1999;729-734.
8. He Q., LaPointe M.C. Interleukin-1beta regulates the human brain natriuretic peptide promoter via Ca(2+)-dependent protein kinase pathways. Hypertension. 35:2000;292-296.
9. Passier R., Zeng H., Frey N., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest. 105:2000;1395-1406.
10. Simpson P.C. Beta-protein kinase C and hypertrophic signaling in human heart failure. Circulation. 99:1999;334-337.
11. Aoki H., Richmond M., Izumo S., Sadoshima J. Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 347:(Pt 1):2000;275-284.
12. Glennon P.E., Kaddoura S., Sale E.M., et al. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res. 78:1996;954-961.
13. Ramirez M.T., Sah V.P., Zhao X.L., et al. The MEKK-JNK pathway is stimulated by alpha1-adrenergic receptor and ras activation and is associated with in vitro and in vivo cardiac hypertrophy. J Biol Chem. 272:1997;14057-14061.
14. Kodama H., Fukuda K., Pan J., et al. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res. 81:1997;656-663.
15. De Windt L.J., Lim H.W., Haq S., Force T., Molkentin J.D. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem. 275:2000;13571-13579.
16. Franch H.A., Shay J.W., Alpern R.J., Preisig P.A. Involvement of pRB family in TGF beta-dependent epithelial cell hypertrophy. J Cell Biol. 129:1995;245-254.
17. Franch H.A., Preisig P.A. NH4Cl-induced hypertrophy is mediated by weak base effects and is independent of cell cycle processes. Am J Physiol. 270:1996;C932-C938.
18. Beltrami A.P., Urbanek K., Kajstura J., et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 344:2001;1750-1757.
19. Kajstura J., Leri A., Finato N., et al. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA. 95:1998;8801-8805.
20. Li J.M., Poolman R.A., Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol. 275:1998;H814-H822.
21. Nozato T., Ito H., Tamamori M., et al. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Jpn Circ J. 64:2000;595-601.
22. Poolman R.A., Brooks G. Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy. J Mol Cell Cardiol. 30:1998;2121-2135.
23. Reiss K., Cheng W., Giorando A., et al. Myocardial infarction is coupled with activation of cyclins and cyclin-dependent kinases in myocytes. Exp Cell Res. 225:1996;44-54.
24. Sadoshima J., Aoki H., Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 80:1997;228-241.
25. Tamamori M., Ito H., Hiroe M., et al. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am J Physiol. 275:1998;H2036-H2040.
26. Bartek J., Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490:2001;117-122.
27. Reed S.I. G1/S regulatory mechanisms from yeast to man. Prog Cell Cycle Res. 2:1996;15-27.
28. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1999;1501-1512.
29. Ohtsubo M., Theodoras A.M., Schumacher J., Roberts J.M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 15:1995;2612-2624.
30. Santoni-Rugiu E., Falck J., Mailand N., Bartek J., Lukas J. Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol. 20:2000;3497-3509.
31. Lukas J., Bartkova J., Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 16:1996;6917-6925.
32. Nozato T., Ito H., Watanabe M., et al. Overexpression of cdk inhibitor p16(INK4a) by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy. J Mol Cell Cardiol. 33:2000;1493-1504.
33. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest. 72:1983;732-738.
34. He T.C., Zhou S., da Costa L.T., et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 95:1998;2509-2514.
35. Lukas J., Aagaard L., Strauss M., Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 375:1995;503-506.
36. Bartkova J., Rajpert-de Meyts E., Skakkebæk N.E., Bartek J. D-type cyclins in adult human testis and testicular cancer: relation to cell type, proliferation, differentiation, and malignancy. J Pathol. 187:1999;573-581.
37. Bartkova J., Thullberg M., Slezak P., et al. Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Gastroenterology. 120:2001;1680-1688.
38. Kajstura J., Zhang X., Reiss K., et al. Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing-induced cardiomyopathy in rats. Circ Res. 74:1994;383-400.
39. Iatropoulos M.J., Williams G.M. Proliferation markers. Exp Toxicol Pathol. 48:1996;175-181.
40. Guidato S., McLoughlin D.M., Grierson A.J., Miller C.C. Cyclin D2 interacts with cdk-5 and modulates cellular cdk-5/p35 activity. J Neurochem. 70:1998;335-340.
41. Inoue K., Sherr C.J. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol. 18:1998;1590-1600.
42. Miwa Y., Sasaguri T., Kosaka C., et al. Differentiation-inducing factor-1, a morphogen of dictyostelium, induces G(1) arrest and differentiation of vascular smooth muscle cells. Circ Res. 86:2000;68-75.
43. Russo G.L., van den Bos C., Sutton A., et al. Phosphorylation of Cdc28 and regulation of cell size by the protein kinase CKII in Saccharomyces cerevisiae. Biochem J. 351:2000;143-150.
44. Kishimoto N., Yamashita I. Cyclic AMP regulates cell size of Schizosaccharomyces pombe through Cdc25 mitotic inducer. Yeast. 16:2000;523-529.
45. Martin-Castellanos C., Blanco M.A., de Prada J.M., Moreno S. The puc1 cyclin regulates the G1 phase of the fission yeast cell cycle in response to cell size. Mol Biol Cell. 11:2000;543-554.
46. Shankland S.J., Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol. 278:2000;F515-F529.
47. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D3: requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene. 17:1998;1027-1037.
48. Kiess M., Gill R.M., Hamel P.A. Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene. 10:1995;159-166.
49. Nagasawa M., Gelfand E.W., Lucas J.J. Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6). Oncogene. 20:2001;2889-2899.
50. Liao H.S., Kang P.M., Nagashima H., et al. Cardiac-specific overexpression of cyclin-dependent kinase 2 increases smaller mononuclear cardiomyocytes. Circ Res. 88:2001;443-450.
51. Liu B., Preisig P. TGF-beta1-mediated hypertrophy involves inhibiting pRB phosphorylation by blocking activation of cyclin E kinase. Am J Physiol. 277:1999;F186-F194.